The new study, published in Neurology, focuses on people with mild cognitive impairment, defined as memory loss that doesn't impair daily life and doesn't qualify for dementia diagnosis.
The study included 13 people in Finland with mild cognitive impairment. They were 70 years old, on average.
For comparison, the study also included 14 older Finnish adults (average age: 65) without memory problems.
Participants got an infusion of a tracer chemical called PIB, which binds to amyloid protein.
Brain Scan Test
The brains of the patient group with memory loss tended to absorb more PIB than the comparison group without memory loss.
"This pattern of increased PIB in patients with [mild cognitive impairment] resembles what's seen in Alzheimer's disease and is suggestive of an early Alzheimer's disease process," Rinne says in an American Academy of Neurology news release.
But Rinne's team didn't follow the participants over time, so it's not clear if any of them developed Alzheimer's disease.
Larger, longer studies are needed to learn whether the PIB test predicts Alzheimer's disease in people with mild cognitive impairment, note the researchers.
The journal notes that Rinne has a consultancy agreement with a branch of GE Health Care, which makes PIB.